JP2020528059A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528059A5
JP2020528059A5 JP2020502669A JP2020502669A JP2020528059A5 JP 2020528059 A5 JP2020528059 A5 JP 2020528059A5 JP 2020502669 A JP2020502669 A JP 2020502669A JP 2020502669 A JP2020502669 A JP 2020502669A JP 2020528059 A5 JP2020528059 A5 JP 2020528059A5
Authority
JP
Japan
Prior art keywords
medical composition
tumor
subject
imaging
moieties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020502669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528059A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/043176 external-priority patent/WO2019018815A1/en
Publication of JP2020528059A publication Critical patent/JP2020528059A/ja
Publication of JP2020528059A5 publication Critical patent/JP2020528059A5/ja
Pending legal-status Critical Current

Links

JP2020502669A 2017-07-21 2018-07-20 悪性腫瘍を同定および診断するためならびに治療的抗腫瘍介入をモニターするための、９９ｍＴｃチルマノセプトおよび関連する分子構造の使用 Pending JP2020528059A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535752P 2017-07-21 2017-07-21
US62/535,752 2017-07-21
PCT/US2018/043176 WO2019018815A1 (en) 2017-07-21 2018-07-20 USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Publications (2)

Publication Number Publication Date
JP2020528059A JP2020528059A (ja) 2020-09-17
JP2020528059A5 true JP2020528059A5 (https=) 2021-08-26

Family

ID=65014640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502669A Pending JP2020528059A (ja) 2017-07-21 2018-07-20 悪性腫瘍を同定および診断するためならびに治療的抗腫瘍介入をモニターするための、９９ｍＴｃチルマノセプトおよび関連する分子構造の使用

Country Status (7)

Country Link
US (1) US20190022259A1 (https=)
EP (1) EP3655107A4 (https=)
JP (1) JP2020528059A (https=)
CN (1) CN111447955A (https=)
CA (1) CA3070494A1 (https=)
IL (1) IL272123A (https=)
WO (1) WO2019018815A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127487A1 (en) * 2019-01-25 2020-07-30 Navidea Biopharmaceuticals, Inc. Compositions and methods for assessing macrophage mediated pathology
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
US20210145989A1 (en) * 2019-09-30 2021-05-20 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
EP4076540A4 (en) * 2020-07-08 2024-02-21 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671256A (en) * 1984-05-25 1987-06-09 Lemelson Jerome H Medical scanning, monitoring and treatment system and method
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
JP2005226021A (ja) * 2004-02-16 2005-08-25 Nihon Medi Physics Co Ltd マンノース受容体親和性化合物
CN114377143A (zh) * 2013-07-22 2022-04-22 康德乐健康414有限责任公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
US20170202969A1 (en) * 2014-07-17 2017-07-20 Larry Schlesinger Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
US10806803B2 (en) * 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2016118188A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
WO2018067751A1 (en) * 2016-10-04 2018-04-12 Navidea Biopharmaceuticals, Inc. Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
MX2019004029A (es) * 2016-10-07 2019-09-27 Navidea Biopharmaceuticals Inc Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
EP3522899A4 (en) * 2016-10-07 2020-05-06 Navidea Biopharmaceuticals, Inc. Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same

Similar Documents

Publication Publication Date Title
JP2020528059A5 (https=)
Poisson et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer
Kao et al. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile
JP2013532629A5 (https=)
Veit-Haibach et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy
Sundram et al. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma
Khan et al. Positron emission tomographic imaging with11C-choline in differential diagnosis of head and neck tumors: comparison with18F-FDG PET
Liepe et al. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization
Parida et al. Metabolic skeletal superscan on 18F-FDG PET/CT in a case of acute lymphoblastic leukemia
Barrington Atlas of clinical positron emission tomography
Hino-Shishikura et al. Biodistribution and radiation dosimetry of [18F]-5-fluorouracil
JP2025503096A5 (https=)
WO2023139203A1 (en) Complexes for cancer treatment and imaging
Hu et al. Functional imaging of interstitial brachytherapy in pancreatic carcinoma xenografts using spectral CT: how does iodine concentration correlate with standardized uptake value of 18FDG-PET-CT?
Cook PET/CT in oncology
Janssen et al. Rapidly growing chest wall mass in a case of sporadic metastatic paraganglioma: imaging with 4 different PET radiopharmaceuticals
Uña-Gorospe et al. Usefulness of single photon emission computed tomography (SPECT)/computed tomography and radioguided surgery in a patient with recurrent pheochromocytoma
Wheat et al. An introduction to nuclear medicine
Mirzaei et al. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors
EP3747874B1 (en) Sodium saccharin having conjugated ligand, derivatives thereof and process for the preparation thereof
Oskoei et al. A Comparative Study of Lung Masses with" Technetium Sestamibi and Pathology Results
Marsh Treatment Planning for Immunomodulatory Radiopharmaceutical Therapy
KR102190674B1 (ko) 리간드 화합물이 결합된 사카린 나트륨, 그 유도체 및 그 제조방법
Ishibashi et al. 99mTc tetrofosmin uptake in lung cancer: A case report
Ell Nuclear medicine maintain its dynamic growth.